Array Biopharma Inc. (NASDAQ: ARRY), a biopharmaceutical company engaged in the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases, has seen a sharp rise in its shares in trading today.
ARRY shares rose to a new 52-week high of $4.10 in trading today. At last check, the stock was trading 6.58% higher at $3.89 on above average volume of 1.48 million.
Array Biopharma shares are gaining momentum in trading today after the company reported positive trial results for its experimental lung cancer drug, selumetinib. The results showed an increase survival by an additional 4.2 months over chemotherapy alone.
ARRY also reported encouraging results of a new melanoma treatment.
Recent Comments